A Study of Zongertinib in People With Lung Cancer

Full Title

Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared with Standard of Care in Patients with Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Jamie Chaft’s office at 646-497-9176.

Protocol
26-122
Phase
Phase III (phase 3)
Disease Status
Relapsed or Refractory
Investigator
Jamie E. Chaft
Fernando Santini
Diseases
Lung Cancer › Lung Cancer, Non-Small Cell
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07195695
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description